Semaphorin 3E expression correlates inversely with plexin D1 during tumor progression

American Journal of Pathology

Volumn 173, Issue 6, 2008, Pages 1873-1881

  Roodink, Ilse ^a   Kats, Gürsah ^a   Van Kempen, Léon ^a   Grunberg, Meritha ^a   Maass, Cathy ^a   Verrijp, Kiek ^a   Raats, Jos ^b,c   Leenders, William ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ModiQuest BV   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLEXIN D1; SEMAPHORIN; SEMAPHORIN 3E; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; COMPETITIVE INHIBITION; CONTROLLED STUDY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; MELANOMA; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 57149095435     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2008.080136     Document Type: Article

References (42)

1. Elder DE: Pathology of melanoma. Clin Cancer Res 2006, 12:2308s-2311s
2. Guerry D, Synnestvedt M, Elder DE, Schultz D: Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993, 100:342S-345S
3. Barnhill RL, Fandrey K, Levy MA, Mihm MC, Jr., Hyman B: Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 1992, 67:331-337
4. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM: Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1997, 7 Suppl 2:S19-S26
5. Clark WH, From L, Bernardino EA, Mihm MC: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969, 29:705-727
6. Ruiter DJ and Van Muijen GN: Markers of melanocytic tumour progression. J Pathol 1998, 186:340-342
7. Johnson JP: Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999, 18:345-357
8. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, Rodriguez-Peralto JL: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004, 164:193-203
9. Bosserhoff AK: Novel biomarkers in malignant melanoma. Clin Chim Acta 2006, 367:28-35
10. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM: Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999, 99:71-80
11. Gherardi E, Love CA, Esnouf RM, Jones EY: The sema domain. Curr Opin Struct Biol 2004, 14:669-678
12. Rohm B, Ottemeyer A, Lohrum M, Puschel AW: Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A. Mech Dev 2000, 93:95-104
13. Nakamura F, Kalb RG, Strittmatter SM: Molecular basis of semaphorin-mediated axon guidance. J Neurobiol 2000, 44:219-229
14. Fujisawa H: Discovery of semaphorin receptors, neuropilin and plexin, and their functions in neural development. J Neurobiol 2004, 59:24-33
15. Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM: Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999, 99:59-69
16. Perala NM, Immonen T, Sariola H: The expression of plexins during mouse embryogenesis. Gene Expr Patterns 2005, 5:355-362
17. Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC: Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 1996, 383:525-528
18. van der Zwaag B, Hellemons AJ, Leenders WP, Burbach JP, Brunner HG, Padberg GW, Van Bokhoven H: PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis. Dev Dyn 2002, 225:336-343
19. Gitler AD, Lu MM, Epstein JA: PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Dev Cell 2004, 7:107-116
20. Torres-Vazquez J, Gitler AD, Fraser SD, Berk JD, Van NP, Fishman MC, Childs S, Epstein JA, Weinstein BM: Semaphorin-plexin signaling guides patterning of the developing vasculature. Dev Cell 2004, 7:117-123
21. Roodink I, Raats J, van der Zwaag B, Verrijp K, Kusters B, Van Bokhoven H, Linkels M, de Waal RM, Leenders WP: Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy? Cancer Res 2005, 65:8317-8323
22. Toyofuku T, Yabuki M, Kamei J, Kamei M, Makino N, Kumanogoh A, Hori M: Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. EMBO J 2007, 26:1373-1384
23. Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, Merte J, Henderson CE, Jessell TM, Kolodkin AL, Ginty DD: Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005, 307:265-268
24. Christensen CR, Klingelhofer J, Tarabykina S, Hulgaard EF, Kramerov D, Lukanidin E: Transcription of a novel mouse semaphorin gene. M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res 1998, 58:1238-1244
25. Kusters B, Leenders WP, Wesseling P, Smits D, Verrijp K, Ruiter DJ, Peters JP, Der Kogel AJ, de Waal RM: Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002, 62:341-345
26. Kusters B, Kats G, Roodink I, Verrijp K, Wesseling P, Ruiter DJ, de Waal RM, Leenders WP: Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene 2007, 26:5808-5815
27. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AM, Sweep CG: EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers 2000, 15:184-191
28. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408
29. Kashani-Sabet M, Shaikh L, Miller JR, III, Nosrati M, Ferreira CM, Debs RJ, Sagebiel RW: NF-kappa B in the vascular progression of melanoma. J Clin Oncol 2004, 22:617-623
30. Christensen C, Ambartsumian N, Gilestro G, Thomsen B, Comoglio P, Tamagnone L, Guldberg P, Lukanidin E: Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res 2005, 65:6167-6177
31. Chauvet S, Cohen S, Yoshida Y, Fekrane L, Livet J, Gayet O, Segu L, Buhot MC, Jessell TM, Henderson CE, Mann F: Gating of Sema3E/PlexinD1 signaling by neuropilin-1 switches axonal repulsion to attraction during brain development. Neuron 2007, 56:807-822
32. Galvin NJ, Vance PM, Dixit VM, Fink B, Frazier WA: Interaction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J Cell Biol 1987, 104:1413-1422
33. Aho S and Uitto J: Two-hybrid analysis reveals multiple direct interactions for thrombospondin 1. Matrix Biol 1998, 17:401-412
34. Trotter MJ, Colwell R, Tron VA: Thrombospondin-1 and cutaneous melanoma. J Cutan Med Surg 2003, 7:136-141
35. Straume O and Akslen LA: Expresson of vascular endothelial growth factor, its receptors (FLT-1. KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001, 159:223-235
36. Han Z, Ni J, Smits P, Underhill CB, Xie B, Chen Y, Liu N, Tylzanowski P, Parmelee D, Feng P, Ding I, Gao F, Gentz R, Huylebroeck D, Merregaert J, Zhang L: Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J 2001, 15:988-994
37. Wang L, Yu J, Ni J, Xu XM, Wang J, Ning H, Pei XF, Chen J, Yang S, Underhill CB, Liu L, Liekens J, Merregaert J, Zhang L: Extracellular matrix protein 1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer Lett 2003, 200:57-67
38. Neufeld G, Shraga-Heled N, Lange T, Guttmann-Raviv N, Herzog Y, Kessler O: Semaphorins in cancer. Front Biosci 2005, 10:751-760
39. Xiang R, Davalos AR, Hensel CH, Zhou XJ, Tse C, Naylor SL: Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res 2002, 62:2637-2643
40. Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin HA, Bourmeyster N, Roche J: Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia 2003, 5:83-92
41. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM: The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002, 4:720-724
42. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S: Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 2004, 23:5131-5137